Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

Cisplatin 10apatinib 5Surgical Procedures, Operative 4Radiotherapy 4Paclitaxel 4Hyperthermic Intraperitoneal Chemotherapy 4Hydralazine 4Gemcitabine 4Carboplatin 4Valproic Acid 3Neoadjuvant Therapy 3Drug Therapy 3Bevacizumab 3taxane 2pembrolizumab 2cetrorelix 2Radiotherapy, Intensity-Modulated 2Probiotics 2Population Groups 2Poly(ADP-ribose) Polymerase Inhibitors 2Metformin 2Laparoscopy 2Indocyanine Green 2Etoposide 2Curcumin 2CP protocol 2Brachytherapy 2spartalizumab 1piperine 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Alendronate × Gynecologic × Clear all
NCT07245381 2025-11-24

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation

Sheba Medical Center

Phase 1/2 Not yet recruiting
65 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡